Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer

Oncologist

Volumn 11, Issue 9, 2006, Pages 1018-1024

  Wilson, Richard H ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Colorectal cancer; NB1011; OSI 7904L; Pemetrexed

Indexed keywords

6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; ADENOSINE A3 RECEPTOR AGONIST; AGO 41699; ANTINEOPLASTIC AGENT; CAPECITABINE; CYCLOSPORIN; DNA TOPOISOMERASE INHIBITOR; EDOTECARIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; GYRASE INHIBITOR; IMIDACRINE; INDISULAM; IRINOTECAN; ISPINESIB; NB 1011; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OBLIMERSEN; OSI 7904 L; OXALIPLATIN; PANITUMUMAB; PEMETREXED; POLY(ADENOSINE DIPHOSPHATE RIBOSE); TEMOZOLOMIDE; THYMECTACIN; THYMIDYLATE SYNTHASE INHIBITOR; UFT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

ANEMIA; ARTICLE; BONE MARROW TOXICITY; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CLINICAL TRIAL; COLORECTAL CANCER; DNA DAMAGE; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; INJECTION SITE REACTION; PRIORITY JOURNAL; RASH; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; ENZYME INHIBITORS; GLUTAMATES; GUANINE; HUMANS; POLY(ADP-RIBOSE) POLYMERASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYMIDYLATE SYNTHASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33749854191     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-9-1018     Document Type: Article

References (95)

1. Rosales J, Leong LA. Chemotherapy for metastatic colorectal cancer. J Natl Compr Canc Netw 2005;3:525-529.
2. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005;23:4553-4560.
3. Moehler M, Teufel A, Galle PR. New chemotherapeutic strategies in colorectal cancer. Recent Results Cancer Res 2005;165:250-259.
4. Kallinowski B. Indications and effect on survival of standard chemotherapy in advanced colorectal cancer. Recent Results Cancer Res 2005;165:245-249.
5. Glimelius B. Benefit-risk assessment of irinotecan in advanced colorectal cancer. Drug Saf 2005;28:417-433.
6. Poston GJ. The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. Eur J Surg Oncol 2005;31:325-330.
7. Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. The Oncologist 2005;10:250-261.
8. Ozer H, Diasio RB. Perspectives in the treatment of colorectal cancer. Semin Oncol 2004;31(6 suppl 15):14-18.
9. Aggarwal S, Chu E. Current therapies for advanced colorectal cancer. Oncology (Williston Park) 2005;19:589-595.
10. Desjardins J, Emerson DL, Colagiovanni DB et al. Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl] amino-1-oxo-2-isoindolynl]-glutaric acid] in mice. J Pharmacol Exp Ther 2004;309:894-902.
11. Beutel G, Glen H, Schoffski P et al. Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors. Clin Cancer Res 2005;11:5487-5495.
12. Falk SJ, Anthoney A, Eatock M et al. Phase II pharmacokinetic (PK) and pharmacodynamic (PD) study of OSI-7904L in previously untreated patients (pts) with advanced gastric or gastroesophageal junction cancer (G/GEJC). 2005 ASCO Annual Meeting. Abstract 4042.
13. John W, Picus J, Blanke CD et al. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer 2000;88:1807-1813.
14. Cripps C, Burnell M, Jolivet J et al. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol 1999;10:1175-1179.
15. Louvet C, de Gramont A. Pemetrexed in advanced colorectal cancer. Oncology (Williston Park) 2004;18(13 suppl 8):56-62.
16. Hochster HS. The role of pemetrexed in the treatment of gastrointestinal malignancy. Clin Colorectal Cancer 2004;4:190-195.
17. de Gramont A, Kindler HL. Pemetrexed in patients with gastrointestinal carcinoma. Semin Oncol 2002;29(17 suppl 5):42-49.
18. Hanauske AR, Chen V, Paoletti P et al. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. The Oncologist 2001;6:363-373.
19. Atkins JN, Jacobs SA, Wieand HS et al. Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program. Clin Colorectal Cancer 2005;5:181-187.
20. Neuteboom ST, Karjian PL, Boyer CR et al. Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, bax, and GADD45 induction. Mol Cancer Ther 2002;1:377-384.
21. Boyer CR, Karjian PL, Wahl GM et al. Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011. Anticancer Drugs 2002;13:29-36.
22. Lackey DB, Groziak MP, Sergeeva M et al. Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase. Biochem Pharmacol 2001;61:179-189.
23. Pegram M, Yeon CH, Ku N et al. Enzyme catalyzed therapeutic activation of NB1011 (N) selectively targets thymidylate synthase (TS)-overexpressing tumor cells: phase I results. J Clin Oncol 2004;22(suppl):3144. [Abstract, ASCO Annual Meeting Proceedings (Post-Meeting Ed.)]
24. Ahmed F, Vyas V, Cornfield A et al. In vitro activation of irinotecan to SN-38 by human liver and intestine. Anticancer Res 1999;19:2067-2071.
25. Kuppens IE, Beijnen J, Schellens JH. Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration. Clin Colorectal Cancer 2004;4:163-180.
26. Schoemaker NE, Kuppens IE, Huinink WW et al. Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours. Cancer Chemother Pharmacol 2005;55:263-270.
27. Soepenberg O, Dumez H, Verweij J et al. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semi-solid matrix capsules in patients with solid tumors. Clin Cancer Res 2005;11:1504-1511.
28. Soepenberg O, Dumez H, Verweij J et al. Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors. J Clin Oncol 2005;23:889-898.
29. Pal A, Khan S, Wang YF et al. Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. Anticancer Res 2005;25:331-341.
30. Lei S, Chien PY, Sheikh S et al. Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice. Anticancer Drugs 2004;15:773-778.
31. Liu X, Lynn BC, Zhang J et al. A versatile prodrug approach for liposomal core-loading of water-insoluble camptothecin anticancer drugs. J Am Chem Soc 2002;124:7650-7651.
32. Sadzuka Y. Effective prodrug liposome and conversion to active metabolite. Curr Drug Metab 2000;1:31-48.
33. Sadzuka Y, Hirotsu S, Hirota S. Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38. Jpn J Cancer Res 1999;90:226-232.
34. Lundberg BB. Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions. Anticancer Drug Des 1998;13:453-461.
35. Saif MW, Diasio RB. Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer 2005;5:27-36.
36. Denny WA. Edotecarin. IDrugs 2004;7:173-177.
37. Yoshinari T, Ohkubo M, Fukasawa K et al. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res 1999;59:4271-4275.
38. Burger AM, Jenkins TC, Double JA et al. Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311. Br J Cancer 1999;81:367-375.
39. Arimori K, Kuroki N, Hidaka M et al. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Pharm Res 2003;20:910-917.
40. Tsuboi K, Tazuma S, Ochi H et al. Hydrophilic bile salts have a cytoprotective effect against cyclosporine A-induced cholestasis through enhanced canalicular membrane fluidity and transporter activity. Hepatol Res 2003;25:38-47.
41. Echevarria-Lima J, Kyle-Cezar FP, Leite DF et al. Expression and activity of multidrug resistance protein 1 in a murine thymoma cell line. Immunology 2005;114:468-475.
42. Tian Q, Zhang J, Tan TM et al. Human Multidrug Resistance Associated Protein 4 Confers Resistance to Camptothecins. Pharm Res 2005 Sep 1; [Epub ahead of print].
43. Ratain MJ, Innocenti F, Vogelzang NJ et al. Modulation of Irinotecan (CPT-11) Toxicity and Pharmacokinetics by Cyclosporine and Phenobarbital. Proc Am Soc Clin Oncol 2001;19:291. Abstract.
44. Calabrese CR, Almassy R, Barton S et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96:56-67.
45. Miknyoczki SJ, Jones-Bolin S, Pritchard S et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003;2:371-382.
46. Vullo D, Innocenti A, Nishimori I et al. Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs? Bioorg Med Chem Lett 2005;15:963-969.
47. Innocenti A, Villar R, Martinez-Merino V, et al. Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides. Bioorg Med Chem Lett 2005 Sep 12; [Epub ahead of print].
48. Laconde G, Pommery N, Depreux P et al. New analogues of the anticancer E7070: synthesis and pharmacology. J Enzyme Inhib Med Chem 2003;18:89-94.
49. van Kesteren C, Zandvliet AS, Karlsson MO et al. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs 2005;23:225-234.
50. Raftopoulos H, Escudier B, Renshaw G et al. A phase II multicenter study of the cyclin-dependent kinase inhibitor indisulam in patients with progressive inoperable and/or metastatic renal cell carcinoma (RCC). J Clin Oncol 2004;22(suppl):4629. [Abstract, ASCO Annual Meeting Proceedings (Post-Meeting Ed.]
51. Ryan DP, Eder J, Appleman L et al. A phase I study of E7070, a chloroindolyl-sulfonamide, in combination with irinotecan in gastrointestinal and thoracic carcinomas. 2005 ASCO Annual Meeting. Abstract 2031.
52. Sunder-Plassmann N, Sarli V, Gartner M et al. Synthesis and biological evaluation of new tetrahydro-beta-carbolines as inhibitors of the mitotic kinesin Eg5. Bioorg Med Chem 2005 Aug 2; [Epub ahead of print].
53. Tao W, South VJ, Zhang Y et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 2005;8:49-59.
54. Sakowicz R, Finer JT, Beraud C et al. Antitumor activity of a kinesin inhibitor. Cancer Res 2004;64:3276-3280.
55. Bar-Yehuda S, Madi L, Silberman D et al. CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model. Neoplasia 2005;7:85-90.
56. Fishman P, Bar-Yehuda S, Ohana G et al. An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B. Oncogene 2004;23:2465-2471.
57. Ohana G, Bar-Yehuda S, Arich A et al. Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101. Br J Cancer 2003;89:1552-1558.
58. Bar-Yehuda S, Madi L, Barak D et al. Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappaB activation: a new class of myeloprotective agents. Exp Hematol 2002;30:1390-1398.
59. Fishman P, Yehuda SB, Stemmer SM et al. CF101 enhances the apoptotic effect of chemotherapy on colon and pancreatic carcinoma cell lines: Molecular mechanisms involved. J Clin Oncol 2004;22(suppl 14):3173. [Abstract, ASCO Annual Meeting Proceedings (Post-Meeting Ed.)]
60. Stemmer SM, Shani A, Klein B et al. A phase II, multi-center study of a new non-cytotoxic A3 adenosine receptor agonist CF101, dose-finding (randomized blinded) in patients (pts)with refractory metastatic colorectal cancer. J Clin Oncol 2004;22(suppl 14):3153. [Abstract, ASCO Annual Meeting Proceedings (Post-Meeting Ed.]
61. Piro LD. Apoptosis, Bcl-2 antisense, and cancer therapy. Oncology (Williston Park) 2004;18(13 suppl 10):5-10.
62. Rosario LA, O'Brien ML, Henderson CJ et al. Cellular response to a glutathione S-transferase P1-1 activated prodrug. Mol Pharmacol 2000;58:167-174.
63. Kauvar LM, Morgan AS, Sanderson PE et al. Glutathione based approaches to improving cancer treatment. Chem Biol Interact 1998;111-112:225-238.
64. Verschraegen CF, Smith HO, Lee FC et al. TLK-286. IDrugs 2004;7:771-781.
65. [No authors listed]. TLK 286. Drugs R D 2004;5(2):116-118.
66. Pukac L, Kanakaraj P, Humphreys R et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005;92:1430-1441.
67. Perez-Galan P, Roue G, Villamor N et al. The proteasome inhibitor bortezomib induces apoptosis in mantle cell lymphoma through generation of ROS species and Noxa activation independent of p53 status. Blood 2005 Sep 15; [Epub ahead of print].
68. Altun M, Galardy PJ, Shringarpure R et al. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res 2005;65:7896-7901.
69. Ross JS, Schenkein DP, Pietrusko R et al. Targeted therapies for cancer 2004. Am J Clin Pathol 2004;122:598-609.
70. Dou QP, Goldfarb RH. Bortezomib (millennium pharmaceuticals). IDrugs 2002;5:828-834.
71. Mackay H, Hedley D, Major P et al. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 2005;11:5526-5533.
72. Ocean AJ, Schnoll-Sussman F, Chen X et al. Phase II study of PS-341 (VELCADE, bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA). 2005 Gastrointestinal Cancers Symposium. [Abstract 31].
73. Kolman A. Epothilone D (Kosan/Roche). Curr Opin Investig Drugs 2004;5:657-667.
74. Rothermel J, Wartmann M, Chen T et al. EPO906 (epothilone B): a promising novel microtubule stabilizer. Semin Oncol 2003;30(3 suppl 6):51-55.
75. Eng C, Kindler HL, Nattam S et al. A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol 2004;15:928-932.
76. Lee FY, Borzilleri R, Fairchild CR et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7:1429-1437.
77. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004;22:2015-2025.
78. Galmarini CM. ABT-751 (Abbott). Curr Opin Investig Drugs 2005;6:623-630.
79. Segreti JA, Polakowski JS, Koch KA et al. Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study. Cancer Chemother Pharmacol 2004;54:273-281.
80. Benson B, Kindler HL, Jodrell D et al. Phase 2 Study of ABT-751 in Patients with Refractory Metastatic Colorectal Carcinoma (CRC). 2005 ASCO Annual Meeting. [Abstract 3537].
81. Qu Z, Griffiths GL, Wegener WA et al. Development of humanized antibodies as cancer therapeutics. Methods 2005;36:84-95.
82. Stein R, Goldenberg DM. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Mol Cancer Ther 2004;3:1559-1564.
83. Blumenthal RD, Osorio L, Hayes MK et al. Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. Cancer Immunol Immunother 2005;54:315-327.
84. Sharkey RM, Hajjar G, Yeldell D et al. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med 2005;46:620-633.
85. Liersch T, Meller J, Kulle B et al. CEA Radioimmunotherapy with 131I-Labetuzumab Improves Survival Post Salvage Resection of Colorectal Cancer Metastases in the Liver. 2005 ASCO Annual Meeting. [Abstract 3627].
86. Ertl HC. Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion. Curr Opin Mol Ther 2002;4:601-605.
87. von Mehren M, Arlen P, Gulley J et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001;7:1181-1191.
88. Horig H, Lee DS, Conkright W et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 2000;49:504-514.
89. von Mehren M, Arlen P, Tsang KY et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res 2000;6:2219-2228.
90. Uyl-de Groot CA, Vermorken JB, Hanna MG Jr. et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 2005;23(17-18):2379-2387.
91. [No authors listed]. Cancer vaccine-Antigenics. BioDrugs 2002;16(1):72-74.
92. Mazzaferro V, Coppa JC, Carrabba MG et al. Vaccination with autologous tumor derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 2003;9:3235-3245.
93. Reinis M. Technology evaluation: TroVax, Oxford BioMedica. Curr Opin Mol Ther 2004;6:436-442.
94. Valle JW, Connolly NB, Harrop R et al. Phase I study of escalating doses of TroVax in patients with advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 2003;22:181. [Abstract 726].
95. Harrop R, Hawkins R, Anthoney A et al. An open label phase II study of modified vaccinia ankara (MVA) expressing the tumor antigen 5T4 given in conjunction with chemotherapy: safety and immunogenicity before, during and after chemotherapy. 2005 ASCO Annual Meeting. [Abstract 2578].